Physician profile
Edward R Harback
NPI 1720075070
$3,346.46
in general payments reported to CMS, 2019-2025
31 companies · $316 in 2025
The $316 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $92.89 · 2021: $322 · 2022: $401 · 2023: $780 · 2024: $792 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,888.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $815.24 | 2019-2025 | |
| Amgen INC. | $530.61 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $288.74 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $281.03 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $156.86 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $139.69 | 2021-2024 | Verquvo |
| Amarin Pharma, INC. | $127.07 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $92.80 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $92.17 | 2022-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $80.70 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.77 | 2023-2024 | Lifevest |
| Atricure, INC. | $67.16 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $63.97 | 2024 | Arcalyst |
| Boston Scientific Corporation | $62.40 | 2019-2024 | Watchman Access System |
| Azurity Pharmaceuticals, INC. | $47.59 | 2023-2024 | Edarbi, Edarbi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.24 | 2019-2023 | Jardiance |
| Cvrx, INC. | $44.59 | 2024-2025 | Barostim Neo System |
| Philips North America LLC | $38.97 | 2023-2024 | (Ck4) Mcot |
| Novo Nordisk INC | $37.70 | 2024 | Wegovy |
| Baxter Healthcare | $33.87 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Kiniksa Pharmaceuticals, LTD. | $29.87 | 2023 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $27.56 | 2019 | |
| Impulse Dynamics (USA) INC. | $26.25 | 2024 | Optimizer |
| Abbott Laboratories | $25.41 | 2023 | Cardiomems |
| Bayer Healthcare Pharmaceuticals INC. | $21.87 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $19.31 | 2023 | Inpefa |
| Edwards Lifesciences Corporation | $16.72 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Heartflow, INC. | $15.20 | 2024 | |
| Cleerly, INC. | $14.79 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Kestra Medical Technology Services, INC. | $14.53 | 2025 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Harback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.